Skip to main content
. 2023 Mar 24;91(4):337–344. doi: 10.1007/s00280-023-04519-6

Table 4.

Number of individual case reports according to VEGFR inhibitors in the WHO database

VEGFR inhibitors Total ADR Polycythemia Hemoglobin increase Hematocrit increase Total AE
Lenvatinib 9641 8 8 2 18
Pazopanib 25,765 18 16 8 42
Axitinib 10,708 21 16 7 44
Bevacizumab 73,693 18 23 17 58
Sorafenib 29,816 9 5 0 14
Sunitinib 36,552 7 9 4 20
Vandetanib 1290 6 4 4 14
Cediranib 157 0 2 0 2
Regorafenib 13,427 1 2 0 3
Semaxanib 19 0 0 0 0

ADR adverse drug reaction; AE adverse event